Zadik, Yehuda http://orcid.org/0000-0002-6062-6529
Raber-Durlacher, Judith E.
Epstein, Joel B.
Majorana, Alessandra
Laheij, Alexa
Bardellini, Elena
Blijlevens, Nicole
Elad, Sharon
Funding for this research was provided by:
Hebrew University of Jerusalem
Article History
Received: 7 June 2024
Accepted: 24 June 2024
First Online: 25 July 2024
Declarations
:
: Not applicable.
: Not applicable.
: Not applicable.
: A. Majorana, E. Bardellini, and N. Blijlevens reported no relevant financial or non-financial interests to disclose.Y. Zadik was a coinvestigator for the study NCT00887263 sponsored by Dr. Falk Pharma GmbH. Y. Zadik received personal fees from SBRBio, and equipment and personal fees for lectures from Erika Carmel and Taro Pharmaceutical Industries.J.E. Raber-Durlacher and A.M.G.A. Laheij received in-kind support from Thor Photomedicine Inc.J.B. Epstein is a consultant for Galera Therapeutics, Janssen Biopharmaceuticals, Nestle Healthcare, Tosk Inc., and a consultant and has funded research from SaNOtize Research and Development Corp. J.B. Epstein is associated Editor-in-Chief for Supportive Care in Cancer.S. Elad is the medical consultant for the study NCT00887263 sponsored by Dr. Falk Pharma GmbH.
: The MASCC/ISOO OCSG Statements have been developed to facilitate the expert-opinion based management of oral complications of cancer therapy where high-quality evidence is lacking. Clinicians should use their judgment when making treatment decisions for individual patients. The Statement authors and the MASCC/ISOO do not guarantee or take responsibility for clinical outcomes in individual patients.